China NMPA Drug Inspection - Bozhou Haomen Traditional Chinese Medicine Pieces Co., Ltd. - Typha pollen

On June 15, 2018, the Henan Provincial Food and Drug Administration in China issued an announcement detailing the discovery of four batches of substandard traditional Chinese medicine products following inspections. The inspections, conducted by Zhengzhou and Luoyang Municipal Food and Drug Inspection Institutes, operated under the regulatory framework of the Chinese Pharmacopoeia (2010 and 2015 editions) and the Henan Province Traditional Chinese Medicine Pieces Processing Standard (2005 edition).

The identified companies and their respective violations include: Anhui Jisongtang Traditional Chinese Medicine Pieces Co., Ltd., whose "Earthworm" (batch 20161001) was substandard in appearance; Bozhou Haomen Traditional Chinese Medicine Pieces Co., Ltd., whose "Typha orientalis" (batch 150401) failed on total ash, extractives, and contained auramine; Tianma (Anhui) Traditional Chinese Medicine Pieces Technology Co., Ltd., with "Stir-fried Atractylodes lancea" (batch 170501) exhibiting substandard moisture and content; and Anhui Zehua Traditional Chinese Medicine Pieces Co., Ltd., also with "Stir-fried Atractylodes lancea" (batch 160801) failing content specifications.

As a result, the Henan Provincial Food and Drug Administration mandated immediate risk control measures. These required relevant regulatory departments to seal, seize, and suspend the sale of the non-compliant drug batches. Furthermore, authorities were instructed to conduct thorough investigations and apply legal penalties against the identified suppliers, underscoring a commitment to ensuring drug quality and public safety.